CD8A and neoplasm: Many immune treatments have now been developed to fight cancer via stimulating immune system to attack cancer cells, but currently a few trials are conducted for hepatocellular carcinoma (HCC) because of low patient response rate of immune checkpoint inhibitors (ICIs) which are associated with decreased tumor infiltration of CD8+ T cells and block dendritic cells (DCs) function in non-immunogenic tumor microenvironment [1,2,3,4,5,6,7,8].